Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

Martin, Michael; Weld, Leisa; Tsai, Theodore F.; Mootrey, Gina T.; Chen, Robert T.; Niu, Manette T.; Cetron, Martín S.; Altman, J.; Ansdell, Vernon; Barnett, Elizabeth D.; Barry, Michèle; Connor, Bradley A.; Freedman, David O.; Gurtman, Alejandra; Jong, Elaine C.; Kozarsky, Phyllis E.; McMullen, Russell; Patterson, Jan E.; Sack, B; Wilson, Mary; Wolfe, Martin S.

doi:10.3201/eid0706.010605

Cited by 127 publications

(78 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Advanced age (65 years and older) was previously identified as a risk factor for systemic adverse events temporally associated with YEL [13][14]. There is some evidence that YEL-AVD and YEL-AND also appear more frequently in persons of advanced age [7].…”

Section: Introductionmentioning

confidence: 99%

“…During this period three types of Typh were available in the U.S.: an oral live-attenuated vaccine (Ty21a); a parental heat-inactivated vaccine (Typhoid vaccine), and a parental capsular polysaccharide vaccine (Typhim Vi). For Hep A, it was estimated that 10% of doses were wasted and that 50% of vaccinees received both doses in the series [13]. The total number of Hep A doses sold was reduced accordingly to estimate the total number of persons vaccinated.…”

Section: Number Of Vaccinated Civilians Typh and Hep Amentioning

confidence: 99%

“…Telephone surveys with health care providers indicated little or no wastage of YEL [13]; therefore, doses distributed were assumed to be a reasonable estimate of the number of persons vaccinated.…”

Section: Number Of Vaccinated Civilians Yelmentioning

confidence: 99%

See 2 more Smart Citations

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Khromava

Eidex

Weld

et al. 2005

Vaccine

197

136

View full text Add to dashboard Cite

Chen, Robert T.; and Cetron, Martin S., "Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events" (2005 AbstractSince 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Number Of Vaccinated Civilians Typh and Hep Amentioning

confidence: 99%

See 1 more Smart Citation

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Khromava

Eidex

Weld

et al. 2005

Vaccine

197

136

View full text Add to dashboard Cite

show abstract

“…The effect of one or more booster vaccinations on the duration of immunity is unknown. Additionally, there are reports of severe infection after vaccination particularly in elderly patients [9], although incidence is rare [10]. Determining the optimal dosing regimens that may minimize boosting would be preferable for the future use of this vaccine.…”

Section: Introductionmentioning

confidence: 99%

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

Hepburn

Kortepeter

Pittman

et al. 2006

Vaccine

View full text Add to dashboard Cite

“…É claro que os dados da história clínica e os antecedentes vacinais também são importantes e devem ser sempre valorizados 14 . Nos casos fatais em que não se dispõe de sangue para sorologia e a pesquisa de vírus foi negativa ou prejudicada, pode-se realizar a detecção de antígenos específicos por imunohistoquímica em tecidos hepáticos conservados em formalina tamponada 25 , ou detectar o genoma viral por RT-PCR do sangue (células e soro) e fígado, preservado sob refrigeração 11,[29][30][31] . Raramente outros tecidos se mostram positivos.…”

Section: Exames Específicos Exames Específicos Exames Específicos Exaunclassified

Febre amarela: reflexões sobre a doença, as perspectivas para o século XXI e o risco da reurbanização

Vasconcelos

2002

Rev. bras. epidemiol.

View full text Add to dashboard Cite

Neste artigo é realizada revisão dos principais aspectos fisiopatológicos, clínicos, epidemiológicos e laboratoriais da febre amarela no Brasil, e também se abordam as linhas gerais do tratamento da doença. São ainda analisados e discutidos os mais recentes surtos e epidemias de febre amarela ocorridos no Brasil, bem como as suas causas e as conseqüências de eventual reurbanização da doença no país, risco que cresce a cada ano à medida que crescem os índices de infestação de Aedes aegypti e a crescente dispersão e transmissão do dengue no país. Finalmente, são comentadas as perspectivas da febre amarela para o século XXI no Brasil.

show abstract

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

Cited by 127 publications

References 29 publications

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

Febre amarela: reflexões sobre a doença, as perspectivas para o século XXI e o risco da reurbanização

Contact Info

Product

Resources

About